Jupiter Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Jupiter Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-974	Closed	-$318K	–	420
2025 Q2	$318K	Sell	974 -13,636	-93%	-$3.77M	﹤0.01%	412
2025 Q1	$3.94M	Sell	14,610 -825	-5%	-$212K	0.04%	298
2024 Q4	$3.63M	Buy	15,435 +6,288	+69%	+$1.65M	0.04%	296
2024 Q3	$2.52M	Buy	+9,147	New	+$2.38M	0.02%	311
2021 Q1	–	Sell	-14,139	Closed	-$1.84M	–	563
2020 Q4	$1.84M	Buy	+14,139	New	+$1.89M	0.02%	422

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jupiter Asset Management's ALNY Position: Q3 2025 in Review

Jupiter Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 974 shares — an estimated $318K sold.

Jupiter Asset Management first reported a position in ALNY in Q4 2020 and held it in 5 quarters. The position peaked at $3.94M in Q1 2025. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

Jupiter Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Jupiter Asset Management sold 974 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $318K.
Jupiter Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Jupiter Asset Management's Alnylam Pharmaceuticals position peaked at $3.94M in Q1 2025.
823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Jupiter Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.